Table 1. Clinicopathological factors and TOP2A overexpression.

			TOP2A overexpression
factor		total	yes	%	no	%	p value
		643	359	55.8	284	44.2
age	50≥	14	87	61.7	54	38.3	0.11
	50<	502	272	54.2	230	45.8
T	*0	2	2	100	0	0	<0.001
	1	366	163	44.5	203	55.5
	2	211	143	32.2	68	67.8
	3	36	26	72.2	10	27.8
	4	28	25	89.3	3	10.7
N	0	422	211	50	211	50	<0.001
	1	172	111	64.5	61	35.5
	2	35	27	77.1	8	22.9
	3	14	4	71.4	10	28.6
Stage	1	302	132	43.7	170	56.3	<0.001
	2	262	166	63.4	96	33.8
	3	79	61	77.2	18	22.8
nuclear grade	1	291	83	28.5	208	71.5	<0.001
	2	161	103	64	58	36
	3	263.6	173	90.6	18	9.4
ER	positive	498	250	50.2	248	49.8	<0.001
	negative	145	109	75.2	36	24.8
PgR	positive	434	218	50.2	216	49.8	<0.001
	negative	209	141	67.5	68	32.5
HER2	positive	134	107	79.3	27	20.7	<0.001
	negative	509	252	49.6	257	50.4
Ki 67	14%>	211	23	10.9	188	89.1	<0.001
	≧14%	432	336	77.8	96	22.2
subtype	luminal A	108	9	8.3	99	91.7	<0.001
	luminal B	315	179	56.8	136	43.2
	HER2	135	107	79.3	28	20.7
	TNBC	85	64	75.3	21	24.7
TOP2A amplified	yes	61	48	78.7	13	21.3	<0.001
	no	582	311	53.4	271	46.6
Adjuvant chemotherapy	yes	309	235	76.1	74	23.9	<0.001
	no	334	124	37.1	210	62.9
Adjuvant radiation therapy	yes	413	232	56.2	181	44.2	0.82
	no	230	127	55.2	103	44.8
recurrence	yes	73	60	82.2	13	17.8	<0.001
	no	570	299	52.5	271	47.5

p value was evaluated using χ² test, ^*T0 means occult breast cancer.

Abbreviations: ER: estrogen receptor; PgR; progesteron receptor; HER2: human epidermal growth factor receptor 2 TNBC: triple negative breast cancer.